Amneal Pharmaceuticals, Inc. (AMRX): Price and Financial Metrics
GET POWR RATINGS... FREE!
AMRX POWR Grades
- Growth is the dimension where AMRX ranks best; there it ranks ahead of 99.4% of US stocks.
- The strongest trend for AMRX is in Sentiment, which has been heading down over the past 177 days.
- AMRX's current lowest rank is in the Momentum metric (where it is better than 7.21% of US stocks).
AMRX Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for AMRX is 7.41 -- better than 94.66% of US stocks.
- AMRX's price/sales ratio is 0.18; that's higher than the P/S ratio of just 5.43% of US stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 12.31 for AMNEAL PHARMACEUTICALS INC; that's greater than it is for 94.27% of US stocks.
- If you're looking for stocks that are quantitatively similar to AMNEAL PHARMACEUTICALS INC, a group of peers worth examining would be AGS, CEMI, NLST, SEAC, and MSGM.
- Visit AMRX's SEC page to see the company's official filings. To visit the company's web site, go to www.amneal.com.
AMRX Valuation Summary
- AMRX's price/sales ratio is 0.2; this is 95.74% lower than that of the median Healthcare stock.
- AMRX's price/sales ratio has moved down 5.5 over the prior 61 months.
Below are key valuation metrics over time for AMRX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| AMRX | 2023-03-24 | 0.2 | 1.4 | -3.1 | 91.7 |
| AMRX | 2023-03-23 | 0.2 | 1.3 | -3.1 | 91.5 |
| AMRX | 2023-03-22 | 0.2 | 1.4 | -3.2 | 92.2 |
| AMRX | 2023-03-21 | 0.2 | 1.6 | -3.6 | 93.4 |
| AMRX | 2023-03-20 | 0.2 | 1.5 | -3.3 | 92.5 |
| AMRX | 2023-03-17 | 0.2 | 1.5 | -3.3 | 92.5 |
AMRX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- AMRX has a Quality Grade of C, ranking ahead of 25.42% of graded US stocks.
- AMRX's asset turnover comes in at 0.514 -- ranking 77th of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows AMRX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.514 | 0.343 | 0.037 |
| 2021-03-31 | 0.495 | 0.320 | 0.031 |
| 2020-12-31 | 0.483 | 0.315 | 0.032 |
| 2020-09-30 | 0.466 | 0.304 | 0.028 |
| 2020-06-30 | 0.440 | 0.283 | 0.063 |
| 2020-03-31 | 0.419 | 0.270 | 0.060 |
AMRX Stock Price Chart Interactive Chart >
AMRX Price/Volume Stats
| Current price | $1.27 | 52-week high | $4.60 |
| Prev. close | $1.29 | 52-week low | $1.24 |
| Day low | $1.24 | Volume | 1,141,700 |
| Day high | $1.30 | Avg. volume | 1,108,658 |
| 50-day MA | $1.99 | Dividend yield | N/A |
| 200-day MA | $2.42 | Market Cap | 385.59M |
Amneal Pharmaceuticals, Inc. (AMRX) Company Bio
Amneal Pharmaceuticals (formerly Impax Laboratories) develops, manufactures, and markets bioequivalent pharmaceutical products. It operates in two segments, Global Pharmaceuticals Division and Impax Pharmaceuticals Division. The company was founded in 1993 and is based in Hayward, California.
Latest AMRX News From Around the Web
Below are the latest news stories about AMNEAL PHARMACEUTICALS INC that investors may wish to consider to help them evaluate AMRX as an investment opportunity.
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q4 2022 Earnings Call TranscriptAmneal Pharmaceuticals, Inc. (NYSE:AMRX) Q4 2022 Earnings Call Transcript March 2, 2023 Operator: Hello, everyone. And welcome to the Amneal Fourth Quarter 2022 Earnings Conference Call. My name is Bruno, and I’ll be operating your call today. I will now turn the call over to Amneal’s Head of Investor Relations, Tony DiMeo. Please go ahead. […] |
Q4 2022 Amneal Pharmaceuticals Inc Earnings CallQ4 2022 Amneal Pharmaceuticals Inc Earnings Call |
Amneal Pharmaceuticals (AMRX) Beats Q4 Earnings and Revenue EstimatesAmneal (AMRX) delivered earnings and revenue surprises of 9.52% and 4.91%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? |
Amneal Announces U.S. FDA Filing Acceptance of Abbreviated New Drug Application for Naloxone Hydrochloride Nasal Spray, USP, 4mgBRIDGEWATER, N.J., March 02, 2023--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Abbreviated New Drug Application (ANDA) for naloxone hydrochloride nasal spray, USP, 4mg, which is the generic version of Narcan® and is used in the treatment of a known or suspected opioid overdose emergency. |
Amneal Reports Fourth Quarter and Full Year 2022 Financial ResultsBRIDGEWATER, N.J., March 02, 2023--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal" or the "Company") announced its results today for the fourth quarter and full year ended December 31, 2022. |
AMRX Price Returns
| 1-mo | -41.20% |
| 3-mo | -36.18% |
| 6-mo | -37.13% |
| 1-year | -69.91% |
| 3-year | -57.67% |
| 5-year | -93.47% |
| YTD | -36.18% |
| 2022 | -58.46% |
| 2021 | 4.81% |
| 2020 | -5.19% |
| 2019 | -64.38% |
| 2018 | -18.74% |
Continue Researching AMRX
Here are a few links from around the web to help you further your research on Amneal Pharmaceuticals Inc's stock as an investment opportunity:Amneal Pharmaceuticals Inc (AMRX) Stock Price | Nasdaq
Amneal Pharmaceuticals Inc (AMRX) Stock Quote, History and News - Yahoo Finance
Amneal Pharmaceuticals Inc (AMRX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...